AbbVie Inc. (ABBV) is a global biopharmaceutical company focused on developing innovative advanced therapies for complex and critical conditions across immunology, oncology, neuroscience, and other specialty areas.
Analyzing a stock's price history alone can mask its true performance in terms of purchasing power. To evaluate AbbVie's genuine investment value, we need to consider inflation's effects. This page presents AbbVie's historical stock prices adjusted using the US Consumer Price Index, revealing the impact of inflation on its value.
Nominal prices are adjusted for stock splits and assume reinvestment of any dividends to reflect total return. Inflation-adjusted prices use May 2026 as the baseline (latest available CPI).
The current value of AbbVie stock is 234.7 (as of the close of Jun 23, 2026), 1.7% lower than the all-time high of 238.76 (Oct 1, 2025).
While the nominal high reached 238.76, the inflation-adjusted peak value was 240.39 on November 21, 2025.
Since January 2, 2013, the inflation-adjusted total return for the stock has been 678.92%, which is equivalent to an annual growth rate of 16.46%.
In nominal values, the total return since this date has been 1,034%, or an annualized rate of 19.75%.
This data presents AbbVie's end-of-month closing levels over time. Inflation-adjusted figures show what past levels would be worth using roughly today's purchasing power based on the latest CPI data, the same present-value method used by the US Inflation Calculator to compare dollar amounts across different years. The latest entry in the table will have equal nominal and adjusted values until the next CPI figures are released.
| Date | Inflation-Adjusted | Nominal value |
|---|---|---|
| Jun 2026 | 234.7 | 234.7 |
| May 2026 | 217.72 | 217.72 |
| Apr 2026 | 212.65 | 211.32 |
| Mar 2026 | 218.92 | 215.72 |
| Feb 2026 | 236.06 | 230.19 |
| Jan 2026 | 227.9 | 221.19 |
| Dec 2025 | 232.51 | 224.83 |
| Nov 2025 | 231.66 | 224.05 |
| Oct 2025 | 214.55 | 214.55 |
| Sep 2025 | 233.4 | 226.21 |
| Aug 2025 | 212.63 | 205.56 |
| Jul 2025 | 191.57 | 184.67 |
| Jun 2025 | 186.81 | 179.81 |
| May 2025 | 187.94 | 180.28 |
| Apr 2025 | 197.43 | 188.99 |
| Mar 2025 | 211.07 | 201.42 |
| Feb 2025 | 211.05 | 200.95 |
| Jan 2025 | 186.5 | 176.79 |
| Dec 2024 | 179.72 | 169.25 |
| Nov 2024 | 185.07 | 174.23 |
| Oct 2024 | 206.15 | 194.18 |
| Sep 2024 | 198.34 | 186.61 |
| Aug 2024 | 197.48 | 185.51 |
| Jul 2024 | 186.58 | 175.12 |
| Jun 2024 | 171.33 | 160.62 |
| May 2024 | 161.11 | 150.99 |
| Apr 2024 | 162.78 | 152.3 |
| Mar 2024 | 181.29 | 168.96 |
| Feb 2024 | 176.4 | 163.35 |
| Jan 2024 | 165.75 | 152.54 |
| Dec 2023 | 155.62 | 142.44 |
| Nov 2023 | 142.84 | 130.88 |
| Oct 2023 | 141.34 | 129.77 |
| Sep 2023 | 147.71 | 135.66 |
| Aug 2023 | 145.99 | 133.75 |
| Jul 2023 | 149.25 | 136.14 |
| Jun 2023 | 133.22 | 121.29 |
| May 2023 | 136.86 | 124.2 |
| Apr 2023 | 150.29 | 136.05 |
| Mar 2023 | 157.86 | 142.18 |
| Feb 2023 | 152.95 | 137.3 |
| Jan 2023 | 147.65 | 131.81 |
| Dec 2022 | 161.28 | 142.83 |
| Nov 2022 | 160.35 | 142.45 |
| Oct 2022 | 145.5 | 129.39 |
| Sep 2022 | 132.59 | 117.43 |
| Aug 2022 | 133.13 | 117.65 |
| Jul 2022 | 142.04 | 125.57 |
| Jun 2022 | 150.18 | 132.78 |
| May 2022 | 146.48 | 127.76 |
| Apr 2022 | 147.61 | 127.34 |
| Mar 2022 | 162.45 | 139.37 |
| Feb 2022 | 150.06 | 127.04 |
| Jan 2022 | 140.28 | 117.69 |
| Dec 2021 | 138.5 | 115.22 |
| Nov 2021 | 118.28 | 98.1 |
| Oct 2021 | 118.23 | 97.58 |
| Sep 2021 | 110.82 | 90.71 |
| Aug 2021 | 124.42 | 101.56 |
| Jul 2021 | 120.05 | 97.8 |
| Jun 2021 | 115.56 | 93.69 |
| May 2021 | 117.21 | 94.15 |
| Apr 2021 | 116.38 | 92.74 |
| Mar 2021 | 112.53 | 88.94 |
| Feb 2021 | 112.82 | 88.55 |
| Jan 2021 | 107.9 | 84.22 |
| Dec 2020 | 112.01 | 87.06 |
| Nov 2020 | 109.42 | 84.97 |
| Oct 2020 | 88.99 | 69.14 |
| Sep 2020 | 90.41 | 70.22 |
| Aug 2020 | 98.99 | 76.78 |
| Jul 2020 | 98.41 | 76.09 |
| Jun 2020 | 101.1 | 77.77 |
| May 2020 | 95.95 | 73.41 |
| Apr 2020 | 85.11 | 65.11 |
| Mar 2020 | 77.23 | 59.48 |
| Feb 2020 | 86.69 | 66.91 |
| Jan 2020 | 82.17 | 63.25 |
| Dec 2019 | 88.96 | 68.21 |
| Nov 2019 | 88.06 | 67.59 |
| Oct 2019 | 79.81 | 61.29 |
| Sep 2019 | 75.06 | 57.51 |
| Aug 2019 | 65.22 | 49.93 |
| Jul 2019 | 66.09 | 50.6 |
| Jun 2019 | 71.19 | 54.41 |
| May 2019 | 75.11 | 57.4 |
| Apr 2019 | 77.9 | 59.4 |
| Mar 2019 | 78.47 | 59.52 |
| Feb 2019 | 77.59 | 58.53 |
| Jan 2019 | 78.95 | 59.3 |
| Dec 2018 | 89.74 | 67.28 |
| Nov 2018 | 91.47 | 68.79 |
| Oct 2018 | 75.29 | 56.81 |
| Sep 2018 | 90.67 | 68.3 |
| Aug 2018 | 92.12 | 69.31 |
| Jul 2018 | 88.57 | 66.6 |
| Jun 2018 | 88.08 | 66.23 |
| May 2018 | 94.21 | 70.73 |
| Apr 2018 | 92.32 | 69.02 |
| Mar 2018 | 89.94 | 66.98 |
| Feb 2018 | 110.32 | 81.96 |
| Jan 2018 | 107.36 | 79.41 |
| Dec 2017 | 92.37 | 67.95 |
| Nov 2017 | 92.52 | 68.1 |
| Oct 2017 | 86.15 | 63.41 |
| Sep 2017 | 84.19 | 62 |
| Aug 2017 | 71.72 | 52.54 |
| Jul 2017 | 66.78 | 48.78 |
| Jun 2017 | 68.61 | 50.15 |
| May 2017 | 62.53 | 45.66 |
| Apr 2017 | 62.5 | 45.61 |
| Mar 2017 | 61.34 | 44.63 |
| Feb 2017 | 58.26 | 42.35 |
| Jan 2017 | 57.76 | 41.85 |
| Dec 2016 | 58.94 | 42.46 |
| Nov 2016 | 57.25 | 41.23 |
| Oct 2016 | 52.44 | 37.82 |
| Sep 2016 | 58.83 | 42.38 |
| Aug 2016 | 59.93 | 43.07 |
| Jul 2016 | 61.98 | 44.5 |
| Jun 2016 | 57.35 | 41.24 |
| May 2016 | 58.48 | 41.92 |
| Apr 2016 | 56.92 | 40.64 |
| Mar 2016 | 53.04 | 37.69 |
| Feb 2016 | 50.93 | 36.04 |
| Jan 2016 | 51.24 | 36.23 |
| Dec 2015 | 54.82 | 38.69 |
| Nov 2015 | 53.62 | 37.98 |
| Oct 2015 | 54.8 | 38.89 |
| Sep 2015 | 49.59 | 35.21 |
| Aug 2015 | 56.8 | 40.39 |
| Jul 2015 | 63.62 | 45.31 |
| Jun 2015 | 60.62 | 43.17 |
| May 2015 | 60.29 | 42.78 |
| Apr 2015 | 58.84 | 41.54 |
| Mar 2015 | 52.94 | 37.3 |
| Feb 2015 | 55.04 | 38.55 |
| Jan 2015 | 55.14 | 38.46 |
| Dec 2014 | 59.07 | 41.39 |
| Nov 2014 | 62.11 | 43.77 |
| Oct 2014 | 56.65 | 40.14 |
| Sep 2014 | 51.06 | 36.26 |
| Aug 2014 | 48.9 | 34.71 |
| Jul 2014 | 46.22 | 32.86 |
| Jun 2014 | 49.45 | 35.17 |
| May 2014 | 47.69 | 33.86 |
| Apr 2014 | 45.88 | 32.45 |
| Mar 2014 | 45.03 | 31.75 |
| Feb 2014 | 44.88 | 31.45 |
| Jan 2014 | 43.56 | 30.41 |
| Dec 2013 | 46.54 | 32.36 |
| Nov 2013 | 42.69 | 29.69 |
| Oct 2013 | 42.61 | 29.69 |
| Sep 2013 | 38.89 | 27.17 |
| Aug 2013 | 37.09 | 25.88 |
| Jul 2013 | 39.63 | 27.63 |
| Jun 2013 | 35.71 | 24.88 |
| May 2013 | 36.97 | 25.7 |
| Apr 2013 | 39.95 | 27.72 |
| Mar 2013 | 35.02 | 24.32 |
| Feb 2013 | 31.79 | 22.02 |
| Jan 2013 | 31.85 | 21.88 |
How much did an investment in AbbVie really grow each year after accounting for inflation? The following chart contains the inflation-adjusted real annual percentage returns.
The table below shows the returns for AbbVie stock by year, both inflation-adjusted and nominal. You can sort any column by clicking on the header.
Observe how inflation erodes nominal gains, sometimes resulting in a negative real return even when the stock price nominally increased, as in 2019.
| Year | Inflation-Adjusted Return | Nominal Return |
|---|---|---|
| 2024 | 15.49% | 18.82% |
| 2023 | -3.51% | -0.27% |
| 2022 | 16.45% | 23.96% |
| 2021 | 23.65% | 32.35% |
| 2020 | 25.91% | 27.63% |
| 2019 | -0.87% | 1.39% |
| 2018 | -2.85% | -0.99% |
| 2017 | 56.72% | 60.02% |
| 2016 | 7.52% | 9.75% |
| 2015 | -7.2% | -6.53% |
| 2014 | 26.93% | 27.89% |
Annualized returns show the average rate of growth per year, making it easier to compare performance across different time periods. While nominal returns indicate the headline growth, adjusting for inflation reveals the actual change in purchasing power.
This table presents both nominal and inflation-adjusted average annual returns for AbbVie over various trailing periods ending May 31, 2026, offering a clearer view of long-term, real investment performance.
| Period | Avg. Annual Return (Inflation-Adjusted) | Avg. Annual Return (Nominal) |
|---|---|---|
| Last 1 year | 15.84% | 20.76% |
| Last 3 years | 16.74% | 20.58% |
| Last 5 years | 13.18% | 18.25% |
| Last 10 years | 14.05% | 17.91% |
The chart and table below show the nominal and inflation-adjusted value of a hypothetical $100 investment over various long-term historical periods, ending in September 2025.
The inflation-adjusted line, in green, represents the real increase in purchasing power for the initial investment. Observe the gap between both lines, which illustrates the cumulative effect of inflation over time.
Even over just five years, inflation takes a noticeable bite out of investments. Investing $100 in the AbbVie five years ago yielded an 155.47% nominal gain, but the real return (the actual increase in buying power) was 106.87%.
As investment periods get longer, the difference between reported nominal returns and the inflation-adjusted gains usually becomes much greater due to the compounding effect of inflation over time.
| Investment Period | What $100 Grew To (Nominal) | Total Nominal Return (%) | Total Inflation-Adjusted Return (%) |
|---|---|---|---|
| Last 5 years Feb 2021 - Sep 2025 | $255.47 | 155.47% | 106.87% |
| Last 10 years Feb 2016 - Sep 2025 | $627.74 | 527.74% | 358.26% |
AbbVie experiences moderate exposure to inflation throughout its business operations.
AbbVie mitigates these inflationary pressures through several approaches. The company's strong pricing power in specialty pharmaceuticals allows it to adjust prices of patented medications in line with or above inflation in many markets, though this ability varies by country due to different healthcare systems and regulations.
Additionally, AbbVie employs strategic long-term contracts with suppliers and manufacturers to stabilize input costs and implements operational efficiency initiatives to offset rising expenses. The company's robust cash flow enables it to continue critical investments despite inflationary environments, while its diverse product portfolio provides revenue stability across economic cycles.
AbbVie Inc. is a research-driven biopharmaceutical company that was formed in 2013 when it was spun off from Abbott Laboratories.
The company develops and markets advanced therapies that address some of the world's most complex and serious diseases. AbbVie's portfolio spans multiple therapeutic areas, with particular strength in immunology and oncology. Its flagship drug Humira has been one of the world's top-selling pharmaceuticals, though the company has worked to diversify its revenue streams as Humira faces biosimilar competition.
Headquartered in North Chicago, Illinois, AbbVie employs thousands of scientists, researchers, and other professionals worldwide and maintains a consistent focus on innovation through significant R&D investment. AbbVie stock is a component of major indices including the S&P 500.
| Last Close Jun 23, 2026 | 234.7 |
|---|---|
| Highest Oct 1, 2025 | 238.76 |
| Highest, Inflation-Adjusted Nov 21, 2025 | 240.39 |
| Annualized return Since Jan 2, 2013 | 19.75% |
| Annualized return, Inflation-Adjusted Since Jan 2, 2013 | 16.46% |
More in Stocks
Other Inflation-Adjusted Data